Form 4: Intellia Director Georgia Keresty Receives Equity Grant

Intellia Therapeutics director Georgia Keresty was granted 9,200 restricted stock units and 13,300 stock options on June 9, 2026.

Summary

• Director Georgia Keresty received a grant of 9,200 restricted stock units (RSUs) representing a contingent right to receive common stock.
• Director Keresty was also granted 13,300 stock options with an exercise price of $12.89 per share.
• The stock options vest in full on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders.
• Following these transactions, the director's total beneficial ownership of common stock is 41,083 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Equity-based compensation aligns the interests of the director with those of the shareholders.
• The grant indicates continued commitment from the board member to the company's long-term performance.

Negatives

• The issuance of new equity awards results in minor dilution to existing shareholders.

Risks

• The value of the granted equity is subject to market volatility and the future performance of Intellia Therapeutics' stock price.

Future Outlook

The filing does not provide specific forward-looking financial guidance, but the vesting schedule of the options implies the director is expected to remain in her role through at least the next annual meeting of stockholders.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain high-level expertise for oversight of complex R&D pipelines.

Comparison to Industry Standards

• The use of a mix of RSUs and stock options is consistent with standard compensation packages for directors at mid-cap biotechnology firms.
• Vesting schedules tied to annual meetings are a common governance practice to ensure board continuity.

Stakeholder Impact

• Minor dilution for existing shareholders due to the issuance of new equity awards.

Next Steps

• Vesting of the stock options on the earlier of June 9, 2027, or the date of the next annual meeting of stockholders.

Key Dates

Keywords

Intellia Therapeutics, NTLA, Form 4, Insider Trading, Equity Compensation, Biotech